arrow
E

Eduard J. van Beers

burjeel medical city
H指数:31
被引数:3,213

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3trial

米塔匹泛在依赖输血的α-地中海贫血或β-地中海贫血成人中的有效性和安全性(ENERGIZE-T):一项双盲、随机、多中心、安慰剂对照、III期临床试验

2026-09-121
PRE
Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children

在大多数镰状细胞病患者中检测不到羟基脲水平,尤其是在幼儿中

2026-07-030
OAAI
Metabolomics in sickle cell disease: Current knowledge and gaps – A scoping review

镰状细胞病中的代谢组学:现有知识及空白——一篇范围综述

2025-09-060
PREAI
Iron Deficiency in HbSC Disease Treated With Repetitive Phlebotomy Is Associated With Fewer Sickle Cell Disease-Related Complications

HbSC疾病患者经反复放血治疗后,缺铁与较少的镰状细胞病相关并发症相关。

2025-09-040
OAAI
Pharmacokinetic-Guided Reduction of Emicizumab in Patients with Congenital Hemophilia a in the Netherlands: Interim Analysis from the Dosemi Study

荷兰先天性血友病A患者中基于药代动力学的依米珠单抗减量:Dosemi研究的期中分析

BLOOD
IF23.1
2024-11-050
PRE
Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II- Results from the 8-Week Dose-Escalation Period

满足:一项Eurobloodnet多中心、单臂II期临床试验,评估米塔吡范在成人红细胞膜病和先天性红细胞生成障碍性贫血II型患者中的应用——8周剂量递增期结果

BLOOD
IF23.1
2024-11-050
PRE
Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease
2024-06-250
OAAI